Dissociation between duration of action in the forced swim test in mice and nicotinic acetylcholine receptor occupancy with sazetidine, varenicline, and 5-I-A85380

Psychopharmacology

Volumn 217, Issue 2, 2011, Pages 199-210

  Caldarone, Barbara J ^a   Wang, Daguang ^a   Paterson, Neil E ^a   Manzano, Michael ^a   Fedolak, Allison ^a   Cavino, Katie ^a   Kwan, Mei ^a   Hanania, Taleen ^a   Chellappan, Sheela K ^b   Kozikowski, Alan P ^b   Olivier, Berend ^c,d   Picciotto, Marina R ^d   Ghavami, Afshin ^a  

^a PSYCHOGENICS INC   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UTRECHT UNIVERSITY   (Netherlands)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 I A85380; AMOP H OH; Antidepressant; Forced swim; Nicotinic receptor; Receptor occupancy; Sazetidine A; Varenicline

Indexed keywords

5 IODO A 85380; DESIPRAMINE; DIHYDRO BETA ERYTHROIDINE; MECAMYLAMINE; NICOTINIC AGENT; NICOTINIC RECEPTOR BETA2; SAZETIDINE A; SERTRALINE; UNCLASSIFIED DRUG; VARENICLINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT LIKE EFFECT; ARTICLE; BALB CJ MOUSE; BRAIN TISSUE; C57BL 6 MOUSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERANCE; EX VIVO STUDY; FORCED SWIMMING TEST; IN VIVO STUDY; LIGAND BINDING; LOCOMOTION; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RECEPTOR OCCUPANCY; RECEPTOR UPREGULATION; REPEATED DRUG DOSE; STRAIN DIFFERENCE;

ANIMALS; ANTIDEPRESSIVE AGENTS; AZETIDINES; BEHAVIOR, ANIMAL; BENZAZEPINES; BRAIN; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; LIGANDS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MOLECULAR STRUCTURE; MOTOR ACTIVITY; NICOTINIC AGONISTS; PROTEIN BINDING; PYRIDINES; QUINOXALINES; RECEPTORS, NICOTINIC; SWIMMING; TIME FACTORS;

EID: 80054941854     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2271-y     Document Type: Article

References (49)

1. Andreasen JT, Redrobe JP (2009a) Antidepressant-like effects of nicotine and mecamylamine in the mouse forced swim and tail suspension tests: role of strain, test and sex. Behav Pharmacol 20:286-295
2. Andreasen JT, Redrobe JP (2009b) Nicotine, but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests. Behav Brain Res 197:150-156
3. Andreasen JT, Olsen GM, Wiborg O, Redrobe JP (2008) Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests. J Psychopharmacol 23:797-804
4. Andreasen JT, Nielsen EO, Christensen JK, Olsen GM, Peters D, Mirza NR, Redrobe JP (2010) Subtype-selective nicotinic acetylcholine receptor agonists enhance the responsiveness to citalopram and reboxetine in the mouse forced swim test. J Psychopharmacol (in press)
5. Brunzell DH, Mineur YS, Neve RL, Picciotto MR (2009) Nucleus accumbens CREB activity is necessary for nicotine conditioned place preference. Neuropsychopharmacology 34:1993-2001
6. Buckley MJ, Surowy C, Meyer M, Curzon P (2004) Mechanism of action of A-85380 in an animal model of depression. Prog Neuropsychopharmacol Biol Psychiatry 28:723-730 (Pubitemid 38987398)
7. Caldarone BJ, Harrist A, Cleary MA, Beech RD, King SL, Picciotto MR (2004) High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation. Biol Psychiatry 56:657-664 (Pubitemid 39446847)
8. Carlezon WA Jr, Duman RS, Nestler EJ (2005) The many faces of CREB. Trends Neurosci 28:436-445 (Pubitemid 40982557)
9. Cucchiaro G, Xiao Y, Gonzalez-Sulser A, Kellar KJ (2008) Analgesic effects of sazetidine-A, a new nicotinic cholinergic drug. Anesthesiology 109:512-519
10. Djuric VJ, Dunn E, Overstreet DH, Dragomir A, Steiner M (1999) Antidepressant effect of ingested nicotine in female rats of Flinders resistant and sensitive lines. Physiol Behav 67:533-537 (Pubitemid 29488531)
11. Drevets WC, Furey ML (2010) Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry 67:432-438
12. Dulawa SC, Hen R (2005) Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test. Neurosci Biobehav Rev 29:771-783 (Pubitemid 40762599)
13. Ferguson SM, Brodkin JD, Lloyd GK, Menzaghi F (2000) Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist, SIB-1508Y, in the learned helplessness rat model of depression. Psychopharmacology (Berl) 152:295-303
14. Furey ML, Drevets WC (2006) Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebocontrolled clinical trial. Arch Gen Psychiatry 63:1121-1129 (Pubitemid 44498391)
15. Gatto GJ, Bohme GA, Caldwell WS, Letchworth SR, Traina VM, Obinu MC, Laville M, Reibaud M, Pradier L, Dunbar G, Bencherif M (2004) TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. CNS Drug Rev 10:147-166 (Pubitemid 38879108)
16. George TP, Sacco KA, Vessicchio JC, Weinberger AH, Shytle RD (2008) Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study. J Clin Psychopharmacol 28:340-344
17. Harvey SC, Maddox FN, Luetje CW (1996) Multiple determinants of dihydro-beta-erythroidine sensitivity on rat neuronal nicotinic receptor alpha subunits. J Neurochem 67:1953-1959 (Pubitemid 26349668)
18. Janowsky DS, El-Yousef MK, Davis JM, Sekerke HJ (1972) A cholinergic-adrenergic hypothesis of mania and depression. Lancet 2:632-635
19. Ke L, Eisenhour CM, Bencherif M, Lukas RJ (1998) Effects of chronic nicotine treatment on expression of diverse nicotinic acetylcholine receptor subtypes. I. Dose- and time-dependent effects of nicotine treatment. J Pharmacol Exp Ther 286:825-840 (Pubitemid 29003474)
20. Kenny PJ, File SE, Neal MJ (2000) Evidence for a complex influence of nicotinic acetylcholine receptors on hippocampal serotonin release. J Neurochem 75:2409-2414
21. Kozikowski AP, Eaton JB, Bajjuri KM, Chellappan SK, Chen Y, Karadi S, He R, Caldarone B, Manzano M, Yuen PW, Lukas RJ (2009) Chemistry and pharmacology of nicotinic ligands based on 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn- 1-ol (AMOP-H-OH) for possible use in depression. ChemMedChem 4:1279-1291
22. Kroes RA, Burgdorf J, Otto NJ, Panksepp J, Moskal JR (2007) Social defeat, a paradigm of depression in rats that elicits 22-kHz vocalizations, preferentially activates the cholinergic signaling pathway in the periaqueductal gray. Behav Brain Res 182:290-300 (Pubitemid 47101912)
23. Kudryavtseva NN, Bakshtanovskaya IV, Koryakina LA (1991) Social model of depression in mice of C57BL/6J strain. Pharmacol Biochem Behav 38:315-320
24. Langlois X, Te Riele P, Wintmolders C, Leysen JE, Jurzak M (2001) Use of the beta-imager for rapid ex vivo autoradiography exemplified with central nervous system penetrating neurokinin 3 antagonists. J Pharmacol Exp Ther 299:712-717 (Pubitemid 32979686)
25. Levin ED, Rezvani AH, Xiao Y, Slade S, Cauley M, Wells C, Hampton D, Petro A, Rose JE, Brown ML, Paige MA, McDowell BE, Kellar KJ (2010) Sazetidine-A, a selective alpha4beta2 nicotinic receptor desensitizing agent and partial agonist, reduces nicotine self-administration in rats. J Pharmacol Exp Ther 332:933-939
26. Lippiello PM, Beaver JS, Gatto GJ, James JW, Jordan KG, Traina VM, Xie J, Bencherif M (2008) TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity. CNS Neurosci Ther 14:266-277
27. Mihalak KB, Carroll FI, Luetje CW (2006) Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 70:801-805 (Pubitemid 44268437)
28. Mineur YS, Picciotto MR (2010) Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends Pharmacol Sci 31:580-586
29. Mineur YS, Somenzi O, Picciotto MR (2007) Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice. Neuropharmacology 52:1256-1262 (Pubitemid 46527701)
30. National Research Council (2010) Guide for the care and use of laboratory animals, 8th edn. Available at http://www.nap.edu/
31. Overstreet DH (1986) Selective breeding for increased cholinergic function: development of a new animal model of depression. Biol Psychiatry 21:49-58 (Pubitemid 16043733)
32. Paterson NE, Min W, Hackett A, Lowe D, Hanania T, Caldarone B, Ghavami A (2010) The high-affinity nAChR partial agonists varenicline and sazetidine-A exhibit reinforcing properties in rats. Prog Neuropsychopharmacol Biol Psychiatry 34:1455-1464
33. Picciotto MR, Zoli M, Léna C, Bessis A, Lallemand Y, Le Novère N, Vincent P, Merlo-Pich E, Brulet P, Changeux J-P (1995) Abnormal avoidance learning in mice lacking functional highaffinity nicotine receptor in the brain. Nature 374:65-67
34. Picciotto MR, Addy NA, Mineur YS, Brunzell DH (2007) It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog Neurobiol 84:329-342
35. Porsolt RD, Bertin A, Jalfre M (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Thér 229:327-336 (Pubitemid 8225714)
36. Pucilowski O, Overstreet DH, Rezvani AH, Janowsky DS (1993) Chronic mild stress-induced anhedonia: greater effect in a genetic rat model of depression. Physiol Behav 54:1215-1220 (Pubitemid 23343148)
37. Rabenstein RL, Caldarone BJ, Picciotto MR (2006) The nicotinic antagonist mecamylamine has antidepressant-like effects in wildtype but not beta2- or alpha7-nicotinic acetylcholine receptor subunit knockout mice. Psychopharm Berl 189:395-401 (Pubitemid 44772820)
38. Reitstetter R, Lukas RJ, Gruener R (1999) Dependence of nicotinic acetylcholine receptor recovery from desensitization on the duration of agonist exposure. J Pharmacol Exp Ther 289:656-660 (Pubitemid 29191215)
39. Rezvani AH, Slade S, Wells C, Petro A, Lumeng L, Li TK, Xiao Y, Brown ML, Paige MA, McDowell BE, Rose JE, Kellar KJ, Levin ED (2010) Effects of sazetidine-A, a selective alpha4beta2 nicotinic acetylcholine receptor desensitizing agent on alcohol and nicotine self-administration in selectively bred alcoholpreferring (P) rats. Psychopharm Berl 211:161-174
40. Rollema H, Guanowsky V, Mineur YS, Shrikhande A, Coe JW, Seymour PA, Picciotto MR (2009) Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect. Eur J Pharmacol 605:114-116
41. Semba J, Mataki C, Yamada S, Nankai M, Toru M (1998) Antidepressant-like effects of chronic nicotine on learned helplessness paradigm in rats. Biol Psychiatry 43:389-391 (Pubitemid 28139460)
42. Sharples CG, Kaiser S, Soliakov L, Marks MJ, Collins AC, Washburn M, Wright E, Spencer JA, Gallagher T, Whiteaker P, Wonnacott S (2000) UB-165: a novel nicotinic agonist with subtype selectivity implicates the alpha4beta2* subtype in the modulation of dopamine release from rat striatal synaptosomes. J Neurosci 20:2783-2791 (Pubitemid 30220302)
43. Shytle RD, Silver AA, Lukas RJ, Newman MB, Sheehan DV, Sanberg PR (2002) Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry 7:525-535
44. Tizabi Y, Overstreet DH, Rezvani AH, Louis VA, Clark E Jr, Janowsky DS, Kling MA (1999) Antidepressant effects of nicotine in an animal model of depression. Psychopharm Berl 142:193-199 (Pubitemid 29190855)
45. Tizabi Y, Rezvani AH, Russell LT, Tyler KY, Overstreet DH (2000) Depressive characteristics of FSL rats: involvement of central nicotinic receptors. Pharmacol Biochem Behav 66:73-77 (Pubitemid 30317519)
46. Turner JR, Castellano LM, Blendy JA (2010) Nicotinic partial agonists, varenicline and sazetidine-a, have differential effects on affective behavior. J Pharmacol Exp Ther 334:665-672
47. Vieyra-Reyes P, Mineur YS, Picciotto MR, Tunez I, Vidaltamayo R, Drucker-Colin R (2008) Antidepressant-like effects of nicotine and transcranial magnetic stimulation in the olfactory bulbectomy rat model of depression. Brain Res Bull 77:13-18
48. Xiao Y, Fan H, Musachio JL, Wei ZL, Chellappan SK, Kozikowski AP, Kellar KJ (2006) Sazetidine-A, a novel ligand that desensitizes alpha4beta2 nicotinic acetylcholine receptors without activating them. Mol Pharmacol 70:1454-1460 (Pubitemid 44435998)
49. Zwart R, Carbone AL, Moroni M, Bermudez I, Mogg AJ, Folly EA, Broad LM, Williams AC, Zhang D, Ding C, Heinz BA, Sher E (2008) Sazetidine-A is a potent and selective agonist at native and recombinant alpha 4 beta 2 nicotinic acetylcholine receptors. Mol Pharmacol 73:1838-1843 (Pubitemid 351724371)